VYNE Stock Risk & Deep Value Analysis
Vyne Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About VYNE Stock
We analyzed Vyne Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VYNE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is VYNE Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
Competitive Risk
High
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for VYNE?
- âš
Negative or inconclusive VYN201 Phase 2b clinical data
- âš
Failure to secure dilutive or non-dilutive financing
- âš
Key competitor (e.g., Opzelura, Rinvoq) demonstrates superior efficacy/safety
- âš
Delay in VYN201 clinical trial timeline
Unlock VYNE Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Vyne Therapeutics Inc (VYNE) Do?
Market Cap
$19.47M
Sector
Healthcare
Industry
Biotechnology
Employees
13
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Visit Vyne Therapeutics Inc WebsiteIs VYNE Stock Undervalued?
Unlock the full AI analysis for VYNE
Get the complete DVR score, risk analysis, and more
Does VYNE Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding (due to cash burn and risk of dilution) to potentially Expanding (if VYN201 data is overwhelmingly positive and leads to strong IP position)
Moat Sources
1 Identified
Currently, the moat is non-existent. Its durability is entirely contingent on VYN201's clinical success, regulatory approval, and patent strength. Without successful clinical data, intellectual property holds no value.
Moat Erosion Risks
- •Clinical trial failure for VYN201
- •Development of superior competing therapies by larger pharmaceutical companies
- •Patent expiry or successful challenges to VYN201's intellectual property
VYNE Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive VYNE Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated early-May 2026)
- •VYN201 Phase 2b Vitiligo Clinical Data Readout (Anticipated Mid-2026)
Medium-Term (6-18 months)
- •Potential strategic partnership or licensing agreement for VYN201 (Conditional on positive data)
- •Initiation of VYN201 Phase 3 trials (Conditional on positive Phase 2b data and funding)
Long-Term (18+ months)
- •Regulatory approval and commercialization of VYN201
- •Pipeline expansion and diversification beyond VYN201
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for VYNE?
- ✓
VYN201 Phase 2b data for vitiligo (efficacy and safety profile)
- ✓
Cash runway projections and any new financing announcements
- ✓
Updates on potential strategic partnerships or licensing discussions
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VYNE (Vyne Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
